Prostate cancer detection at low prostate specific antigen

Journal of Urology

Volumn 163, Issue 3, 2000, Pages 806-812

  Schröder, Fritz H ^a   Van Der Cruijsen Koeter, Ingrid ^a   De Koning, Harry J ^a   Vis, André N ^a   Hoedemaeker, Robert F ^a   Kranse, Ries ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biopsy; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0343593693     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67809-3     Document Type: Article

References (40)

1. American Urological Association: Executive Committee report. Baltimore: American Urological Association, January 1992
2. American Cancer Society: Guidelines for the cancer-related checkup: an update. Atlanta: American Cancer Society, 1993
3. Adami, H. O., Baron, J. A. and Rothman, K. J.: Ethics of a prostate cancer screening trial. Lancet, 343: 958, 1994
4. Parker, S. L., Tong, T., Bolden, S. et al: Cancer statistics, 1997. CA Cancer J Clin, 47: 5, 1997
5. Hankey, B. F., Fever, E. J., Clegg, L. X. et al: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst, 91: 107, 1999
6. de Koning, H. J., Auvinen, A., Berenguer Sanchez, A. et al: Large-scale randomized prostate cancer screening trials; program performances in the ERSPC- and PLCO-trials (European Randomized Screening for Prostate Cancer- and Prostate, Lung, Colorectal and Ovary cancer trials). Submitted for publication, 1999
7. Bangma, C. H., Kranse, R., Blijenberg, B. et al: The value of screening tests in the detection of prostate cancer. Part I: results of a retrospective evaluation of 1726 men. Urology, 46: 773, 1995
8. Bangma, C. H., Kranse, R., Blijenberg, B. G. et al: The value of screening tests in the detection of prostate cancer. Part II: a stimulation of the role of the free/total prostate-specific antigen ratio, age-specific reference ranges, and PSA density. Urology, 46: 779, 1995
9. Bangma, C. H., Kranse, R., Blijenberg, B. G. et al: The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol, 157: 544, 1997
10. Rietbergen, J. W. W., Kranse R., Kirkels, W. J. et al: Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer: improving the efficiency of early detection. Br J Urol, 79: 57, 1997
11. Beemsterboer, P. M. M., Kranse, R., de Koning, H. J. et al: Changing role of 3 screening modalities in the European Randomized Study of Screening for Prostate Cancer (Rotterdam). Int J Cancer, 84: 437, 1999
12. Kranse, R., Beemsterboer, P., Rietbergen, J. et al: Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate, 39: 316, 1999
13. Auvinen, A., Rietbergen, J. B., Denis, L. J. et al: Prospective evaluation plan for randomised trials of prostate cancer screening. International Prostate Cancer Screening Trial Evaluation Group. J Med Screening, 3: 97, 1996
14. Schröder, F. H., van der Maas, P., Beemsterboer, P. M. et al: Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst, 90: 1817, 1998
15. Terris, M. K., McNeal, J. E. and Stamey, T. A.: Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol, 148: 829, 1992
16. Eskew, L. A., Bare, R. L. and McCullough, D. L.: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol, 157: 199, 1997
17. Gleason, D. F.: Histologic grading of prostate cancer: a perspective. Hum Pathol, 23: 273, 1992
18. Hoedemaeker, R. F., Rietbergen, J. B., Kranse, R. et al: Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. World J Urol, 15: 339, 1997
19. Schröder, F. H., Hermanek, P., Denis, L. et al: The TNM classification of prostate cancer. Prostate, suppl., 4: 129, 1992
20. Colberg, J. W., Smith, D. S. and Catalona, W. J.: Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng/ml. J Urol, 149: 507, 1993
21. Carvalhal, G. F., Smith, D. S., Mager, D. E. et al: Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol, 161: 835, 1999
22. Yu, H., Harris, R. E., Gao, Y. T. et al: Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States. Int J Epidemiol, 20: 76, 1991
23. Chodak, G. W., Thisted, R. A., Gerber, G. S. et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med, 330: 242, 1994
24. Albertsen, P. C., Hanley, J. A., Gleason, D. F. et al: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA, 280: 975, 1998
25. Lu-Yao, G. L. and Yao, S. L.: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet, 349: 906, 1997
26. Ohori, M., Wheeler, T. M., Dunn, J. K. et al: The pathological features and prognosis of prostate cancers detectable with current diagnostic tests. J Urol, 152: 1714, 1994
27. Partin, A. W., Lee, B. R., Carmichael, M. et al: Radical prostatectomy for high grade disease: a reevaluation 1994. J Urol, 151: 1583, 1994
28. Zincke, H., Bergstralh, E. J., Blute, M. L. et al: Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol, 12: 2254, 1994
29. Lodding, P., Aus, G., Bergdahl, S. et al: Characteristics of screening detected prostate cancer in men 50 to 66-year-old with 3 to 4 ng/ml prostate specific antigen. J Urol, 159: 899, 1998
30. Schröder, F. H., van der Cruijsen-Koeter, I., Vis, A. et al: PSA based early detection of prostate cancer. Validation of screening without rectal examination. Submitted for publication, 1999
31. Stenman, U. H., Leinonen, J., Alfthan, H. et al: A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res, 51: 222, 1991
32. España, F., Royo, M., Martínez, M. et al: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. J Urol, 160: 2081, 1998
33. Catalona, W. J., Partin, A. W., Chan, D. W. et al: Detection of prostate cancer with % FPSA and HK2 when PSA is 2-4 ng/ml. J Urol, suppl., 161: 207, abstract 794, 1999
34. Krumholtz, J., Carvalhal, G. F., Ramos, C. G. et al: Total PSA cut-off of 2.5 ng/ml correlates with favorable pathologic features of prostate cancer. J Urol, suppl., 161: 99, abstract 371, 1999
35. Becker, C., Lilja, H., Piironen, T. et al: HK2 measurements in a randomly selected, population based screening for prostate cancer. J Urol, suppl., 161: 320, abstract 1233, 1999
36. Boeken Kruger, A. E., Schröder, F. H., Thomas, C. et al: Sensitive and specific assay of human kallikrein 2 (hK2) in serum improves prostate cancer diagnosis. J Urol, suppl., 161: 317, abstract 1222, 1999
37. Kwiatkowski, M., Recker, F., Piironen, T. et al: Various ratios of human glandular Kallikrein (hK2) to free and total PSA improve discrimination between G1-G2 and G3 prostate tumors. J Urol, suppl., 161: 239, abstract 920, 1999
38. Djavan, B., Remzi, M., Seitz, C. et al: Serum-PSA, F/T PSA, PSAD, PSA-TZ and PSA velocity: early detection of prostate cancer in men with serum PSA levels of 2.5 to 4.0 ng/ml. J Urol, suppl., 161: 95, abstract 355, 1999
39. Catalona, W. J., Partin, A. W., Chan, D. W. et al: Prostate cancer detection in men with serum PSA concentrates of 2.8 to 4.0 ng./ml. and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA, 277: 1452, 1998
40. Recker F., Kwiatkowski M., Graber S. et al: Ergebnisse der Pilotstudie zum Prostateakarzinom Screening im Kanton Aargau. Presented at Swiss Urological Association, Freiburg, Switzerland, 1999